| David H Murman, MD | |
|
111 Colchester Ave, Burlington, VT 05401-1473 | |
| (802) 875-1237 | |
| Not Available |
| Full Name | David H Murman |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 17 Years |
| Location | 111 Colchester Ave, Burlington, Vermont |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1073704763 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 0012601 (Vermont) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Central Vermont Medical Center | Barre, VT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Central Vermont Medical Center Inc | 9335138817 | 204 |
News Archive
More than half of all retired people aged 65 and over report sleeping at least 7.5 hours per night, and between the hours of 11 p.m. and 7:30 a.m., contrary to commonly held assumptions that most elderly go to bed early and have trouble sleeping through the night, according to a study by researchers at the University of Pittsburgh's Sleep and Chronobiology Center (SCC) and University Center for Social and Urban Research (UCSUR).
Celgene International Sàrl, a subsidiary of Celgene Corporation today announced that the U.S. Food and Drug Administration has assigned a Priority Review designation to the supplemental New Drug Application for the use of ABRAXANE (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in combination with gemcitabine for the first-line treatment of patients with advanced pancreatic cancer.
Akorn, Inc. a niche generic pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted approval of the Company's Abbreviated New Drug Application (ANDA) supplement for Erythromycin Ophthalmic Ointment USP 3.5 g. The company intends to begin shipping the product immediately.
Because gastrointestinal stromal tumors (GIST) are sensitive to the targeted small molecule therapy imatinib, oncologists tend to treat all patients with metastatic GIST with this drug. However, because this rare type of cancer is caused by different genetic mutations, imatinib does not help all patients equally.
› Verified 4 days ago
| Entity Name | University Of Vermont Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1659309615 PECOS PAC ID: 3779491071 Enrollment ID: O20040406001047 |
News Archive
More than half of all retired people aged 65 and over report sleeping at least 7.5 hours per night, and between the hours of 11 p.m. and 7:30 a.m., contrary to commonly held assumptions that most elderly go to bed early and have trouble sleeping through the night, according to a study by researchers at the University of Pittsburgh's Sleep and Chronobiology Center (SCC) and University Center for Social and Urban Research (UCSUR).
Celgene International Sàrl, a subsidiary of Celgene Corporation today announced that the U.S. Food and Drug Administration has assigned a Priority Review designation to the supplemental New Drug Application for the use of ABRAXANE (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in combination with gemcitabine for the first-line treatment of patients with advanced pancreatic cancer.
Akorn, Inc. a niche generic pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted approval of the Company's Abbreviated New Drug Application (ANDA) supplement for Erythromycin Ophthalmic Ointment USP 3.5 g. The company intends to begin shipping the product immediately.
Because gastrointestinal stromal tumors (GIST) are sensitive to the targeted small molecule therapy imatinib, oncologists tend to treat all patients with metastatic GIST with this drug. However, because this rare type of cancer is caused by different genetic mutations, imatinib does not help all patients equally.
› Verified 4 days ago
| Entity Name | Central Vermont Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1831374362 PECOS PAC ID: 9335138817 Enrollment ID: O20040510001034 |
News Archive
More than half of all retired people aged 65 and over report sleeping at least 7.5 hours per night, and between the hours of 11 p.m. and 7:30 a.m., contrary to commonly held assumptions that most elderly go to bed early and have trouble sleeping through the night, according to a study by researchers at the University of Pittsburgh's Sleep and Chronobiology Center (SCC) and University Center for Social and Urban Research (UCSUR).
Celgene International Sàrl, a subsidiary of Celgene Corporation today announced that the U.S. Food and Drug Administration has assigned a Priority Review designation to the supplemental New Drug Application for the use of ABRAXANE (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in combination with gemcitabine for the first-line treatment of patients with advanced pancreatic cancer.
Akorn, Inc. a niche generic pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted approval of the Company's Abbreviated New Drug Application (ANDA) supplement for Erythromycin Ophthalmic Ointment USP 3.5 g. The company intends to begin shipping the product immediately.
Because gastrointestinal stromal tumors (GIST) are sensitive to the targeted small molecule therapy imatinib, oncologists tend to treat all patients with metastatic GIST with this drug. However, because this rare type of cancer is caused by different genetic mutations, imatinib does not help all patients equally.
› Verified 4 days ago
| Entity Name | Central Vermont Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023028784 PECOS PAC ID: 9335138817 Enrollment ID: O20051220000393 |
News Archive
More than half of all retired people aged 65 and over report sleeping at least 7.5 hours per night, and between the hours of 11 p.m. and 7:30 a.m., contrary to commonly held assumptions that most elderly go to bed early and have trouble sleeping through the night, according to a study by researchers at the University of Pittsburgh's Sleep and Chronobiology Center (SCC) and University Center for Social and Urban Research (UCSUR).
Celgene International Sàrl, a subsidiary of Celgene Corporation today announced that the U.S. Food and Drug Administration has assigned a Priority Review designation to the supplemental New Drug Application for the use of ABRAXANE (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in combination with gemcitabine for the first-line treatment of patients with advanced pancreatic cancer.
Akorn, Inc. a niche generic pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted approval of the Company's Abbreviated New Drug Application (ANDA) supplement for Erythromycin Ophthalmic Ointment USP 3.5 g. The company intends to begin shipping the product immediately.
Because gastrointestinal stromal tumors (GIST) are sensitive to the targeted small molecule therapy imatinib, oncologists tend to treat all patients with metastatic GIST with this drug. However, because this rare type of cancer is caused by different genetic mutations, imatinib does not help all patients equally.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| David H Murman, MD 111 Colchester Ave, Burlington, VT 05401-1473 Ph: () - | David H Murman, MD 111 Colchester Ave, Burlington, VT 05401-1473 Ph: (802) 875-1237 |
News Archive
More than half of all retired people aged 65 and over report sleeping at least 7.5 hours per night, and between the hours of 11 p.m. and 7:30 a.m., contrary to commonly held assumptions that most elderly go to bed early and have trouble sleeping through the night, according to a study by researchers at the University of Pittsburgh's Sleep and Chronobiology Center (SCC) and University Center for Social and Urban Research (UCSUR).
Celgene International Sàrl, a subsidiary of Celgene Corporation today announced that the U.S. Food and Drug Administration has assigned a Priority Review designation to the supplemental New Drug Application for the use of ABRAXANE (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in combination with gemcitabine for the first-line treatment of patients with advanced pancreatic cancer.
Akorn, Inc. a niche generic pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted approval of the Company's Abbreviated New Drug Application (ANDA) supplement for Erythromycin Ophthalmic Ointment USP 3.5 g. The company intends to begin shipping the product immediately.
Because gastrointestinal stromal tumors (GIST) are sensitive to the targeted small molecule therapy imatinib, oncologists tend to treat all patients with metastatic GIST with this drug. However, because this rare type of cancer is caused by different genetic mutations, imatinib does not help all patients equally.
› Verified 4 days ago
William Alexander Manning, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 111 Colchester Ave, Burlington, VT 05401 Phone: 802-847-0000 | |
Dr. Richard Page Hudson Iii, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 111 Colchester Ave, Fahc Emergency Department, Burlington, VT 05401 Phone: 802-847-3982 Fax: 802-847-5963 | |
Dr. Daniel John Ackil, DO Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 111 Colchester Ave, Burlington, VT 05401 Phone: 802-847-2434 | |
John I Ellis, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 111 Colchester Ave, Mchv Campus - Ed, Burlington, VT 05401 Phone: 802-847-3982 | |
Elizabeth N Malik, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 111 Colchester Ave, Burlington, VT 05401 Phone: 802-847-0000 | |
Dr. David Ward Clauss, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 111 Colchester Ave, Fahc Emergency Department, Burlington, VT 05401 Phone: 802-847-3982 Fax: 802-847-5963 |